BioInvent International AB (BINV)

Currency in SEK
28.450
+0.850(+3.08%)
Closed·
BINV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.80028.450
52 wk Range
22.70041.600
Key Statistics
Prev. Close
28.45
Open
27.7
Day's Range
26.8-28.45
52 wk Range
22.7-41.6
Volume
98.12K
Average Volume (3m)
107.01K
1-Year Change
-0.5245%
Book Value / Share
10.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BINV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
90.000
Upside
+216.34%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

BioInvent International AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

BioInvent International Company Profile

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1 clinical trial for the treatment of solid tumors. It has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; collaboration and supply agreement with MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; and licensing agreement with CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Employees
124
Market
Sweden

Compare BINV to Peers and Sector

Metrics to compare
BINV
Peers
Sector
Relationship
P/E Ratio
−5.5x−2.6x−0.6x
PEG Ratio
−0.27−0.090.00
Price/Book
2.6x1.5x2.6x
Price / LTM Sales
7.3x4.9x3.4x
Upside (Analyst Target)
232.1%123.1%42.0%
Fair Value Upside
Unlock23.0%5.8%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 90.000
(+216.34% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Oct 29, 2025
EPS / Forecast
-1.96 / --
Revenue / Forecast
3.32M / --
EPS Revisions
Last 90 days

People Also Watch

5.52
CANTA
+9.96%
12.380
DMYDb
+1.81%
57.80
OVZON
+4.90%
11.100
VICOR
-1.25%

FAQ

What Is the BioInvent International (BINV) Share Price Today?

The live BioInvent International share price today is 28.450

What Stock Exchange Does BioInvent International (BINV) Trade On?

BioInvent International is listed and trades on the Stockholm Stock Exchange.

What Is the Ticker (Stock Symbol) for BioInvent International?

The stock symbol (also called a 'ticker') for BioInvent International is "BINV."

What Is the Current BioInvent International Market Cap?

As of today, BioInvent International market capitalisation is 1.87B.

What Is BioInvent International's (BINV) Earnings Per Share (TTM)?

The BioInvent International EPS is currently -4.93 (Trailing Twelve Months).

When Is the Next BioInvent International Earnings Date?

BioInvent International's next earnings report will be released on 26 Feb 2026.

Is BINV a Buy or Sell From a Technical Analyst Perspective?

Based on today's BioInvent International moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has BioInvent International Stock Split?

BioInvent International has split 8 times. (See the BINV stock split history page for full effective split date and price information.)

How Many Employees Does BioInvent International Have?

BioInvent International has 124 employees.

What is the current trading status of BioInvent International (BINV)?

As of 21 Jan 2026, BioInvent International (BINV) is trading at a price of 28.450, with a previous close of 28.450. The stock has fluctuated within a day range of 26.800 to 28.450, while its 52-week range spans from 22.700 to 41.600.

What Is BioInvent International (BINV) Price Target According to Analysts?

The average 12-month price target for BioInvent International is SEK90.000, with a high estimate of SEK90 and a low estimate of SEK90. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +216.34% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.